Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2022, affirmed 2022 financial guidance1 and...

Related Keywords

United Kingdom ,Germany ,Japan ,Italy ,Ireland ,Russia ,Dublin ,France ,Spain ,Ukraine ,Erwinaze Erwinase ,Oxybate Xywav ,Epidiolex Epidyolex ,Redx Pharma ,Bruce Cozadd ,Roche Ltd ,Oncology Review Program ,Jazz Pharmaceuticals ,Drug Administration ,Nasdaq ,Gw Pharmaceuticals ,Company Annual Report On Form ,Exchange Commission ,Prnewswire Jazz Pharmaceuticals ,Corporate Development ,Sumitomo Pharma Co Ltd ,European Medicines Agency ,Company Quarterly Report On Form ,Investigational New Drug ,Marketing Authorization Application ,Orphan Drug Exclusivity ,Idiopathic Hypersomnia ,Myoclonic Atonic Seizures ,Lennox Gastaut Syndrome ,Tuberous Sclerosis Complex ,Dravet Syndrome ,Biologics Licensing Application ,Real Time Oncology Review Program ,Werewolf Therapeutics ,Strategic Divestiture ,Axsome Therapeutics ,Lower Limb Muscle ,Modified Ashworth Scale ,Fast Track Designation ,American Association ,Cancer Research Annual Meeting ,Own Equity ,Convertible Instruments ,Exchangeable Senior ,Effective Tax ,Euro Term Loan ,Exchangeable Senior Notes ,Jazz Pharmaceutical ,Adjusted Consolidated ,Jazz Pharmaceutical Securities ,Annual Report ,Quarterly Report ,Certain Line Items ,Jazz Pharmaceuticals Plc ,